Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Bortezomib Retreatment in Relapsed Multiple Myeloma (MM): Results from a Binational, Multicenter Retrospective Survey

Irena Hrusovsky, Berthold Emmerich, Albert von Rohr, Monika Engelhardt, Jerome Voegeli, Christian Taverna, Robert Olie, Harold Pliskat, Claas Frohn, Georg Hess

Blood (2008) 112 (11): 2775.

https://doi.org/10.1182/blood.V112.11.2775.2775

Published: 2008

Journal Articles

Biologic and Clinical Markers for Outcome after Fludarabine (F) or F Plus Cyclophosphamide (FC) - Comprehensive Analysis of the CLL4 Trial of the GCLLSG.

Stephan Stilgenbauer, Barbara F. Eichhorst, Raymonde Busch, Thorsten Zenz, Dirk Winkler, Andreas Bühler, Valentin Goede, Clemens M Wendtner, Peter Lichter, Berthold Emmerich, Michael Hallek, Hartmut Döhner

Blood (2008) 112 (11): 2089.

https://doi.org/10.1182/blood.V112.11.2089.2089

Published: 2008

Journal Articles

Bortezomib Retreatment in Relapsed Multiple Mycelia - A Retrospective Multicenter Survey.

Irena Hrusovsky, MD, Berthold Emmerich, MD, Monika Engelhardt, MD, Martin Kornacker, MD, Claudia-Nanette Gann, MD, Harold Pliskat, PhD, Georg Hess, MD

Blood (2007) 110 (11): 2720.

https://doi.org/10.1182/blood.V110.11.2720.2720

Published: 2007

Journal Articles

Minimal Residual Disease (MRD) Kinetics after Autologous Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) Correlate to IgH VH Mutational Status and Predict Post Transplant Outcome: Real Time ASO-IgH PCR Results of the GCLLSG CLL3 Protocol.

Matthias Ritgen, MD, Peter Dreger, MD, Stephan Stilgenbauer, MD, Nils von Neuhoff, PhD, Hildegard T. Greinix, MD, Bernd Hertenstein, MD, Norbert Schmitz, MD, Berthold Emmerich, MD, Michael Hallek, MD, Hartmut Döhner, MD, Michael Kneba, MD, PhD

Blood (2004) 104 (11): 147.

https://doi.org/10.1182/blood.V104.11.147.147

Published: 2004

Journal Articles

Prognostic Impact of the Serum Levels of Soluble CD23 in B-Cell Chronic Lymphocytic Leukemia

Irmgard Langenmayer, Michael Hallek, Berthold Emmerich, Dagmar Adorf, Christoph Nerl, Theodor Zwingers, Wolfgang U Knauf, Bärbel Ehlers, Birgitt Mohr, Eckhard Thiel

Blood (1997) 89 (11): 4241.

https://doi.org/10.1182/blood.V89.11.4241

Published: 1997

NARROW

Bortezomib Retreatment in Relapsed Multiple Myeloma (MM): Results from a Binational, Multicenter Retrospective Survey

Biologic and Clinical Markers for Outcome after Fludarabine (F) or F Plus Cyclophosphamide (FC) - Comprehensive Analysis of the CLL4 Trial of the GCLLSG.

Bortezomib Retreatment in Relapsed Multiple Mycelia - A Retrospective Multicenter Survey.

Minimal Residual Disease (MRD) Kinetics after Autologous Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) Correlate to IgH VH Mutational Status and Predict Post Transplant Outcome: Real Time ASO-IgH PCR Results of the GCLLSG CLL3 Protocol.

Prognostic Impact of the Serum Levels of Soluble CD23 in B-Cell Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Bortezomib Retreatment in Relapsed Multiple Myeloma (MM): Results from a Binational, Multicenter Retrospective Survey

Biologic and Clinical Markers for Outcome after Fludarabine (F) or F Plus Cyclophosphamide (FC) - Comprehensive Analysis of the CLL4 Trial of the GCLLSG.

Bortezomib Retreatment in Relapsed Multiple Mycelia - A Retrospective Multicenter Survey.

Minimal Residual Disease (MRD) Kinetics after Autologous Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) Correlate to IgH VH Mutational Status and Predict Post Transplant Outcome: Real Time ASO-IgH PCR Results of the GCLLSG CLL3 Protocol.

Prognostic Impact of the Serum Levels of Soluble CD23 in B-Cell Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only